Nanomedicine : nanotechnology, biology, and medicine最新文献_第5页

PLGA-Based nanocarriers in drug delivery: Advances in block copolymer engineering, hybrid platforms, and clinical translation 高分子纳米载体：靶向药物递送的进展、挑战和未来展望。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-01-05 DOI: 10.1016/j.nano.2025.102896

Pranal Chhetri

{"title":"PLGA-Based nanocarriers in drug delivery: Advances in block copolymer engineering, hybrid platforms, and clinical translation","authors":"Pranal Chhetri","doi":"10.1016/j.nano.2025.102896","DOIUrl":"10.1016/j.nano.2025.102896","url":null,"abstract":"<div><div>Poly (lactic-co-glycolic acid) (PLGA) nanoparticles have become one of the most extensively investigated carriers in nanomedicine, significantly valued for their biodegradable, biocompatible, and flexible nature in tailoring drug release. Modern Pharmaceutical research has moved well beyond conventional PLGA formulations, exploring advanced designs like surface modified systems, hybrid systems, and new generation block copolymers. This review gives comprehensive insights on recent advancement and developments in PLGA based nanoparticles, including less explored combinations such as POEGMA and PDXO based blocks, and natural polymer hybrids that offer unique targeting and stability advantages. It also gives in depth clarity in persistent challenges like poor loading of hydrophilic drugs, burst release, opsonization and manufacturing scalability, and highlight some important strategies that have been being developed to address them, like microfluidic fabrication. In conclusion, it is outlined how PLGA based nanosystems can evolve into robust, precision drug delivery systems with a clear path towards clinical adoption.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102896"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma 131i标记抗甘聚糖-3抗体在肝细胞癌靶向放射免疫治疗中的应用

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-02-03 DOI: 10.1016/j.nano.2026.102907

Ming-Hui Yang , Kuo-Pin Chuang , Hsin-Rou Liang , Po-Chiao Huang , Shih-Chang Chuang , Tzu-Chuan Ho , Ying-Fong Huang , Cheng-Hui Yuan , Yu-Chang Tyan

{"title":"Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma","authors":"Ming-Hui Yang , Kuo-Pin Chuang , Hsin-Rou Liang , Po-Chiao Huang , Shih-Chang Chuang , Tzu-Chuan Ho , Ying-Fong Huang , Cheng-Hui Yuan , Yu-Chang Tyan","doi":"10.1016/j.nano.2026.102907","DOIUrl":"10.1016/j.nano.2026.102907","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is a highly lethal malignancy and a leading cause of cancer-related mortality worldwide, largely due to its asymptomatic progression and the limited therapeutic efficacy available for advanced stages. Glypican-3 (GPC3), a membrane-bound heparan sulfate proteoglycan, is overexpressed in approximately 70–80% of HCC cases while remaining absent in healthy liver tissue, making it an ideal theranostic target. In this study, we developed a novel <sup>131</sup>I-labeled anti-GPC3 antibody. This radiopharmaceutical was synthesized with a high labeling yield (~93%) and demonstrated robust in vitro stability (with >81% radiochemical purity retained at 120 h). In vitro MTT assays revealed dose-dependent cytotoxicity, with cell viability significantly reduced to 27.7% at a dose of 6 μCi. In vivo evaluation in a spontaneous HCC mouse model confirmed strong GPC3 expression restricted specifically to tumor tissues. Biodistribution analysis further revealed preferential tumor accumulation (~1.3% injected dose per gram) with minimal radioactivity in non-target organs. Collectively, these findings demonstrate the feasibility and therapeutic potential of <sup>131</sup>I-GPC3 as a targeted theranostic radiopharmaceutical for HCC and other GPC3-expressing malignancies.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102907"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cisplatin(IV)-fatty acid prodrug-bound albumin nanoparticles: In vitro, in silico, and in vivo evaluation in breast cancer therapy 顺铂(IV)-脂肪酸前药结合白蛋白纳米颗粒：体外、硅和体内对乳腺癌治疗的评估。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-02-09 DOI: 10.1016/j.nano.2026.102910

Oly Katari , Vivek Yadav , Rajkumar R , Prabha Garg , Sanyog Jain

{"title":"Cisplatin(IV)-fatty acid prodrug-bound albumin nanoparticles: In vitro, in silico, and in vivo evaluation in breast cancer therapy","authors":"Oly Katari , Vivek Yadav , Rajkumar R , Prabha Garg , Sanyog Jain","doi":"10.1016/j.nano.2026.102910","DOIUrl":"10.1016/j.nano.2026.102910","url":null,"abstract":"<div><div>The therapeutic outcome of cisplatin (CP) in triple-negative breast cancer (TNBC) is hindered by irreversible protein binding, systemic toxicities, and resistance development. Therefore, we synthesized three CP(IV) prodrugs of fatty acids (FAs) possessing reversible albumin binding to overcome these shortcomings. Among these, CP-OA depicted the most cytotoxicity in MDA-MB-231 and 4T1 cells, showing synergistic effect and potential dose reduction. Albumin nanoparticles of CP-OA (CP-OA NPs) were optimized using a Design of Experiments (DoE) approach, yielding a particle size of 189.6 nm, PDI 0.23, and 77.47% entrapment efficiency. CP-OA NPs showed improved drug loading, sustained release, enhanced apoptosis (∼5 folds), ROS generation (∼2 folds), and mitochondrial depolarization (∼6 folds). The <em>in vivo</em> studies portrayed reduction in tumor volume (5.64-folds), organ toxicities and hemolysis (6.18-folds) compared to marketed formulation. Overall, this study highlights the therapeutic potential of CP(IV) prodrug bound albumin nanoparticles in improving therapeutic efficacy and safety of CP in TNBC.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102910"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In situ vaccination with tumor microenvironment-responsive nanoprodrug for enhanced cancer immunotherapy 肿瘤微环境反应性纳米前药原位接种增强肿瘤免疫治疗。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-01-06 DOI: 10.1016/j.nano.2025.102895

Dan Liu , Yue Han , Meiyu Shang , Jiping Huo , Zhigang Zhao

{"title":"In situ vaccination with tumor microenvironment-responsive nanoprodrug for enhanced cancer immunotherapy","authors":"Dan Liu , Yue Han , Meiyu Shang , Jiping Huo , Zhigang Zhao","doi":"10.1016/j.nano.2025.102895","DOIUrl":"10.1016/j.nano.2025.102895","url":null,"abstract":"<div><div><em>In situ</em> vaccination (ISV) has emerged as a promising strategy in cancer immunotherapy. However, systemic administration of immunostimulatory agents or chemotherapeutics often results in toxicity and immune-related adverse events. Herein, we developed a tumor microenvironment (TME)-responsive nanoprodrug by conjugating the Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPLA) with the chemotherapeutic agent doxorubicin (DOX) <em>via</em> a matrix metalloproteinase-9 (MMP-9)-cleavable peptide and polyethylene glycol (PEG), forming an amphiphilic conjugate that spontaneously self-assembled into stable, injectable nanoparticles (named as MPPD NPs). Upon reaching the TME, MMP-9-mediated cleavage of the peptide linker triggered the disintegration of the nanoparticle outer structure, resulting in localized DOX release. The released DOX induced immunogenic cell death of tumor cells, promoting the release of damage-associated molecular patterns and initiating immune responses. Simultaneously, the residual MPLA-PEG core nanoparticles (MP NPs) were internalized by dendritic cells, triggering the TLR4 signaling pathway to enhance tumor antigen presentation and cytokines secretion, thereby eliciting robust CD8<sup>+</sup> T cell-mediated cytotoxic immune response. <em>In vivo</em>, this nanoprodrug not only effectively suppressed tumor progression and extended survival time in tumor-bearing mice but also significantly reduced DOX-associated cardiotoxicity. RNA sequencing of tumor tissue further confirmed that MPPD NPs potentiate ISV by activating immune-related pathways. This study presented a safe and effective ISV strategy that elicits robust tumor-specific immunity and provides a new insight into the design of combinatorial chemo-immunotherapeutic nanoplatform.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102895"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PEGylated heptamethine cyanine nanoparticles improve photothermal efficacy and elicit durable anti-tumour immunity in breast cancer mouse model 聚乙二醇化七甲基菁氨酸纳米颗粒提高乳腺癌小鼠模型的光热功效并引发持久的抗肿瘤免疫。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-01-23 DOI: 10.1016/j.nano.2026.102906

Gong Yi Yong , Sastiya Kampaengsri , Susan Ling Ling Hoe , Lu Ping Tan , Anyanee Kamkaew , Chin Siang Kue

{"title":"PEGylated heptamethine cyanine nanoparticles improve photothermal efficacy and elicit durable anti-tumour immunity in breast cancer mouse model","authors":"Gong Yi Yong , Sastiya Kampaengsri , Susan Ling Ling Hoe , Lu Ping Tan , Anyanee Kamkaew , Chin Siang Kue","doi":"10.1016/j.nano.2026.102906","DOIUrl":"10.1016/j.nano.2026.102906","url":null,"abstract":"<div><div>Photothermal therapy (PTT) induces immunogenic tumour cell death and stimulates both innate and adaptive immunity. In our previous study, we showed promising <em>in vitro</em> and <em>in ovo</em> anti-tumour efficacies of a quinoline-modified heptamethine cyanine (QuCy7) encapsulated with polyethylene glycol (PEG), forming QuCy7@mPEG NPs. This study evaluated its anti-tumour efficacy and immunomodulatory effects in a syngeneic breast cancer mouse model. QuCy7@mPEG NPs induced stronger hyperthermic effect (~45 °C) compared to QuCy7 alone (~40 °C), significantly delayed tumour growth (84.9%) and achieved 50% tumour elimination. Cytokine analysis showed elevated levels of IL-6, TNF-α, IFN-γ and IL-17A, along with reduced TGF-β expression. Post-treatment, increased infiltration of neutrophils, IL-6-producing M1-like macrophages, T-helper 1, and cytotoxic T cells was observed. Notably, QuCy7@mPEG NPs enhanced long-term tumour-specific immunity, evidenced by rapid CD4<sup>+</sup> effector memory T cells activation upon tumour re-challenge. These findings highlight the potential of QuCy7@mPEG NPs as an immune-stimulatory photothermal agent for cancer treatment.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102906"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Computational prediction and SLN formulation of Narcissin for reverse transcriptase inhibition and controlled drug delivery applications 水仙素在逆转录酶抑制和控制给药应用中的计算预测和SLN配方。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-01-23 DOI: 10.1016/j.nano.2026.102904

Taha Alqahtani , Hanan M. Alharbi , Stalin Arulsamy , Swati Mayur Keny , Malarkodi Velraj , Kumarappan Chidambaram , Panneerselvam Theivendren

{"title":"Computational prediction and SLN formulation of Narcissin for reverse transcriptase inhibition and controlled drug delivery applications","authors":"Taha Alqahtani , Hanan M. Alharbi , Stalin Arulsamy , Swati Mayur Keny , Malarkodi Velraj , Kumarappan Chidambaram , Panneerselvam Theivendren","doi":"10.1016/j.nano.2026.102904","DOIUrl":"10.1016/j.nano.2026.102904","url":null,"abstract":"<div><div>The aim of this paper was to construct a stable drug delivery mechanism of Narcissin, which is phytoconstituent of <em>Aerva lanata</em> that has Reverse Transcriptase potential of anti-breast cancer. The Rand Forest Classifier was the most successful machine learning algorithm with an accuracy of 86.43 and independent test set validation of 80.85. High binding affinity to Narcissin (−13.3 kcal/mol) with five hydrogen bonds and positive hydrophobic interactions were observed in molecular docking. Simulations of Narcissin-Reverse Transcriptase complex using molecular dynamics revealed that it did not exhibit significant changes in RMSD, which meant that the complex was stable. MMGBSA analysis has displayed a good binding free energy of −51.12 kcal/mol with the van der Waals forces playing a major role (−62.2 kcal/mol). The Narcissin loaded solid lipid nanoparticles (SLN) had the highest encapsulation efficiency (90.12%), mean particle size of 80 nm, and zeta potential of −20 mV. In vitro release experiments revealed a zero-order, diffusion-controlled release, which was controlled and the cumulative release at pH 7.4 was 93.24%. The MTT assay exhibited dose- and time-dependent cytotoxicity particularly at 100 μg/mL indicating that Narcissin has a potential to be used as a bioactive agent in the treatment of breast cancer in SLN-based formulations.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102904"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From platelets to paracrine signals: A review of PRP, exosomes, and cell-based interventions for skin repair and rejuvenation 从血小板到旁分泌信号：PRP、外泌体和基于细胞的皮肤修复和年轻化干预的综述。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-01-22 DOI: 10.1016/j.nano.2026.102905

Elaheh Esmaeili , Iman Rad

{"title":"From platelets to paracrine signals: A review of PRP, exosomes, and cell-based interventions for skin repair and rejuvenation","authors":"Elaheh Esmaeili , Iman Rad","doi":"10.1016/j.nano.2026.102905","DOIUrl":"10.1016/j.nano.2026.102905","url":null,"abstract":"<div><h3>Background</h3><div>Regenerative dermatology has advanced from basic wound care to therapies targeting skin repair biology, with platelet-rich plasma (PRP), exosomes, and cell-based treatments as key innovations.</div></div><div><h3>Objective</h3><div>This review synthesizes evidence on the mechanisms, efficacy, safety, and challenges of these interventions for skin repair and rejuvenation, highlighting integrative strategies.</div></div><div><h3>Methods</h3><div>A comprehensive literature review of preclinical and clinical studies was conducted, focusing on therapeutic mechanisms and translational barriers. <em>Results:</em> PRP delivers growth factors (PDGF, TGF-β, VEGF, EGF) to promote angiogenesis and tissue remodeling. Exosomes transfer microRNAs and proteins to modulate oxidative stress and collagen homeostasis. Cell-based therapies enable structural restoration, including gene-corrected grafts. All show favorable safety, but barriers exist: PRP lacks standardization, exosomes face manufacturing challenges, and cell-based therapies encounter high costs and regulatory hurdles.</div></div><div><h3>Conclusion</h3><div>These modalities represent a shift toward biological restoration. Their integration, guided by robust trials and scalable manufacturing, will define regenerative dermatology's future.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102905"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146043766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody functionalized targeted siRNA nanodelivery epigenetically controls Slug-Vimentin cross-talk for neuroblastoma inhibition 抗体功能化靶向siRNA纳米递送表观遗传控制鼻涕虫-波形蛋白串扰抑制神经母细胞瘤。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-03-01 Epub Date: 2026-01-06 DOI: 10.1016/j.nano.2025.102899

Mohammed Nadim Sardoiwala , Boddu Mrunalini , Devangi Ghosh , Mohd Ayoub , Surajit Karmakar , Subhasree Roy Choudhury

{"title":"Antibody functionalized targeted siRNA nanodelivery epigenetically controls Slug-Vimentin cross-talk for neuroblastoma inhibition","authors":"Mohammed Nadim Sardoiwala , Boddu Mrunalini , Devangi Ghosh , Mohd Ayoub , Surajit Karmakar , Subhasree Roy Choudhury","doi":"10.1016/j.nano.2025.102899","DOIUrl":"10.1016/j.nano.2025.102899","url":null,"abstract":"<div><div>Neuroblastoma is an aggressive extracranial cancer having causative factors including epigenetic alterations and histone modifications. The epigenetic master regulator, Bmi1 is the essential molecule in the progression of neuroblastoma (NB). The existing small molecule inhibitor-based epigenetic targeted therapy has limitations of aberrant activity and delivery challenges. However, the siRNA degradation limits the therapeutic efficacy and could be countered by the nanodelivery system. Indeed, specific targeting of cancer improves the therapeutic effect. GD2 is the specific molecular hallmark of NB that's how for the first time, anti-GD2 decorated Bmi1 siRNA encapsulated HSA (Human Serum Albumin)-Chitosan nanohybrid is being employed to inhibit targeted epigenetic therapy for NB. The results have shown endowed transfection efficiency, impressive knockdown efficiency, and remarkable tumor growth restriction by improving Bmi1 siRNA stability. The restriction of cell migration and significant downregulation of metastatic hallmark, vimentin reflects the anti-metastatic action of nanohybrids. The first-time exploration of molecular mechanism has revealed Bmi1 mediated Sox2/Slug/Vimentin signaling in NB progression that is inhibited by our nanohybrids. Thus, the present study divulges the immense potential of HSA-Chitosan nanohybrids as the new delivery system for nucleic acid having the promising caliber to be anti-GD2 decorated targeted epigenetic therapeutics in the treatment of NB.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"72 ","pages":"Article 102899"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

WITHDRAWN: DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. 为子宫颈癌接种DNA疫苗；RALA介导的聚合物微针基因传递的新技术平台。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-02-27 DOI: 10.1016/j.nano.2026.102923

A A Ali, C M McCrudden, J McCaffrey, J W McBride, G Cole, N J Dunne, T Robson, A Kissenpfennig, R F Donnelly, H O McCarthy

引用次数: 0

Rational design of nanotherapy for ulcerative colitis: New strategies, mechanistic approaches, and translational challenges 溃疡性结肠炎纳米治疗的合理设计：新策略、机制途径和转化挑战。

IF 4.6 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-31 DOI: 10.1016/j.nano.2025.102894

Wenyuan Xu , Qiulin Deng , Liuhong Chen , Xishun Zhou , Yao Dong , Chenran Ren , Xi Zeng , Deliang Cao

{"title":"Rational design of nanotherapy for ulcerative colitis: New strategies, mechanistic approaches, and translational challenges","authors":"Wenyuan Xu , Qiulin Deng , Liuhong Chen , Xishun Zhou , Yao Dong , Chenran Ren , Xi Zeng , Deliang Cao","doi":"10.1016/j.nano.2025.102894","DOIUrl":"10.1016/j.nano.2025.102894","url":null,"abstract":"<div><div>Ulcerative colitis (UC), a chronic mucosal inflammatory condition, is hampered by the systemic side effects, variable responses, and limited sustained efficacy of current drugs like immunosuppressants and biologics. Recent advancements in nanotechnology have led to the emergence of groundbreaking drug delivery platforms, which offer new avenues for addressing the therapeutic challenges of UC. This article aims to provide a comprehensive review of the rational design principles underlying UC nanotherapeutics, with a focus on leveraging the unique pathophysiological features of the disease for the development of nanosystems endowed with dual-targeting capabilities and multi-stimulus responsiveness. We also discussed the multifaceted mechanisms of action of these nanotherapies, which extend beyond mere drug delivery to include immunomodulation, gut barrier repair, and gut microbiota remodeling. Furthermore, the challenges in clinical translation are critically evaluated, encompassing biosafety, manufacturing quality, and the preclinical-human gap. This article would serve as a resource for understanding nanotherapies for UC.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102894"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0